Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1410

1.

Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease.

Jørgensen MB, Idorn T, Rydahl C, Hansen HP, Bressendorff I, Brandi L, Wewer Albrechtsen NJ, van Hall G, Hartmann B, Holst JJ, Knop FK, Hornum M, Feldt-Rasmussen B.

J Clin Endocrinol Metab. 2019 Oct 14. pii: dgz048. doi: 10.1210/clinem/dgz048. [Epub ahead of print]

PMID:
31608934
2.

Ghrelin does not directly stimulate secretion of glucagon-like peptide-1.

Jepsen SL, Vestergaard ET, Larraufie P, Gribble FM, Reimann F, Jørgensen JOL, Holst JJ, Kuhre RE.

J Clin Endocrinol Metab. 2019 Oct 14. pii: dgz046. doi: 10.1210/clinem/dgz046. [Epub ahead of print]

PMID:
31608930
3.

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures.

Lundgren JR, Færch K, Witte DR, Jonsson AE, Pedersen O, Hansen T, Lauritzen T, Holst JJ, Vistisen D, Jørgensen ME, Torekov SS, Johansen NB.

Cardiovasc Diabetol. 2019 Oct 5;18(1):130. doi: 10.1186/s12933-019-0937-7.

4.

Effects of a High-Protein/Moderate-Carbohydrate Diet on Appetite, Gut Peptides, and Endocannabinoids-A Preview Study.

Tischmann L, Drummen M, Gatta-Cherifi B, Raben A, Fogelholm M, Hartmann B, Holst JJ, Matias I, Cota D, Mensink RP, Joris PJ, Westerterp-Plantenga MS, Adam TC.

Nutrients. 2019 Sep 21;11(10). pii: E2269. doi: 10.3390/nu11102269.

5.

Gluco-metabolic effects of oral and intravenous alcohol administration in men.

Lanng ARR, Gasbjerg LS, Bergmann NC, Bermann S, Helsted MM, Gillum MP, Hartmann B, Holst JJ, Vilsbøll T, Knop FK.

Endocr Connect. 2019 Sep 1. pii: EC-19-0317.R1. doi: 10.1530/EC-19-0317. [Epub ahead of print]

6.

Paracrine Crosstalk between Intestinal L- and D-cells Controls Secretion of Glucagon-Like Peptide-1 in mice.

Jepsen SL, Grunddal KV, Wewer Albrechtsen NJ, Engelstoft MS, Gabe MBN, Jensen EP, Ørskov C, Poulsen SS, Rosenkilde MM, Pedersen J, Gribble FM, Reimann F, Deacon CF, Schwartz TW, Christ AD, Martin RE, Holst JJ.

Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00239.2019. [Epub ahead of print]

PMID:
31503512
7.

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.

Iepsen EW, Zhang J, Hollensted M, Madsbad S, Hansen T, Holst JJ, Jørgensen NR, Holm JC, Torekov SS.

J Bone Miner Metab. 2019 Aug 30. doi: 10.1007/s00774-019-01034-8. [Epub ahead of print]

PMID:
31471646
8.

Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice.

Ørgaard A, Jepsen SL, Holst JJ.

Islets. 2019;11(5):103-111. doi: 10.1080/19382014.2019.1587976. Epub 2019 Aug 30.

9.

Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans.

Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, van Eijk H, Canfora EE, Blaak EE.

Sci Rep. 2019 Aug 29;9(1):12515. doi: 10.1038/s41598-019-48775-0.

10.

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats.

Baldassano S, Gasbjerg LS, Kizilkaya HS, Rosenkilde MM, Holst JJ, Hartmann B.

Front Endocrinol (Lausanne). 2019 Aug 6;10:492. doi: 10.3389/fendo.2019.00492. eCollection 2019.

11.

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity.

Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N, Gillum MP, Treebak JT, Jessen N.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5703-5714. doi: 10.1210/jc.2019-01081.

PMID:
31390002
12.

The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake.

Jensen CH, Kosmina R, Rydén M, Baun C, Hvidsten S, Andersen MS, Christensen LL, Gastaldelli A, Marraccini P, Arner P, Jørgensen CD, Laborda J, Holst JJ, Andersen DC.

EBioMedicine. 2019 Aug;46:368-380. doi: 10.1016/j.ebiom.2019.07.070. Epub 2019 Aug 3.

13.

A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.

Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E, Frystyk J, Holst JJ, Thomsen HS, Madsbad S, Larsen TM, Haugaard SB, Krarup T.

Diabetologia. 2019 Jul 23. doi: 10.1007/s00125-019-4956-4. [Epub ahead of print]

PMID:
31338545
14.

GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals.

Larsson M, Patrone C, von Euler M, Holst JJ, Nathanson D.

Cardiovasc Diabetol. 2019 Jul 15;18(1):91. doi: 10.1186/s12933-019-0896-z.

15.

Glucagon Receptor Signaling and Glucagon Resistance.

Janah L, Kjeldsen S, Galsgaard KD, Winther-Sørensen M, Stojanovska E, Pedersen J, Knop FK, Holst JJ, Wewer Albrechtsen NJ.

Int J Mol Sci. 2019 Jul 5;20(13). pii: E3314. doi: 10.3390/ijms20133314. Review.

16.

Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery.

Jorsal T, Wewer Albrechtsen NJ, Christensen MM, Mortensen B, Wandall E, Langholz E, Friis S, Worm D, Ørskov C, Støving RK, Andries A, Juhl CB, Sørensen F, Forman JL, Falkenhahn M, Musholt PB, Theis S, Larsen PJ, Holst JJ, Vrang N, Jelsing J, Vilsbøll T, Knop FK.

J Clin Endocrinol Metab. 2019 Jul 5. pii: jc.2019-00062. doi: 10.1210/jc.2019-00062. [Epub ahead of print]

PMID:
31276156
17.

Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy.

Steiner E, Breuer R, Kazianka L, Wewalka M, Stimpfl T, Reiter B, Holst JJ, Miholic J.

Pancreas. 2019 Aug;48(7):953-957. doi: 10.1097/MPA.0000000000001361.

PMID:
31268979
18.

Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes.

Justinussen T, Madsbad S, Holst JJ, Bojsen-Møller KN.

Expert Rev Endocrinol Metab. 2019 Jul;14(4):243-257. doi: 10.1080/17446651.2019.1628639. Epub 2019 Jun 19.

PMID:
31215828
19.

The diurnal variation of bone formation is attenuated in adult patients with type 2 diabetes.

Hygum K, Starup-Linde JK, Harsløf T, Joergensen NR, Hartmann B, Holst JJ, Langdahl B.

Eur J Endocrinol. 2019 Jun 1. pii: EJE-19-0309.R1. doi: 10.1530/EJE-19-0309. [Epub ahead of print]

PMID:
31189129
20.

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

Holst JJ.

Lancet. 2019 Jul 6;394(10192):4-6. doi: 10.1016/S0140-6736(19)31350-9. Epub 2019 Jun 8. No abstract available.

PMID:
31186119
21.

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.

Behary P, Tharakan G, Alexiadou K, Johnson N, Wewer Albrechtsen NJ, Kenkre J, Cuenco J, Hope D, Anyiam O, Choudhury S, Alessimii H, Poddar A, Minnion J, Doyle C, Frost G, Le Roux C, Purkayastha S, Moorthy K, Dhillo W, Holst JJ, Ahmed AR, Prevost AT, Bloom SR, Tan TM.

Diabetes Care. 2019 Aug;42(8):1446-1453. doi: 10.2337/dc19-0449. Epub 2019 Jun 8.

22.

Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study).

Knorr S, Bytoft B, Lohse Z, Boisen AB, Clausen TD, Jensen RB, Damm P, Beck-Nielsen H, Holst JJ, Hartmann B, Møller HJ, Højlund K, Gravholt CH, Jensen DM.

Diabetes Care. 2019 Aug;42(8):1560-1568. doi: 10.2337/dc19-0571. Epub 2019 Jun 4.

PMID:
31167890
23.

Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.

Anholm C, Kumarathurai P, Jürs A, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Holst JJ, Madsbad S, Sajadieh A, Haugaard SB.

Diabetol Metab Syndr. 2019 May 31;11:42. doi: 10.1186/s13098-019-0438-6. eCollection 2019.

24.

Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.

Øhrstrøm CC, Worm D, Højager A, Andersen D, Holst JJ, Kielgast UL, Hansen DL.

Diabetes Obes Metab. 2019 Sep;21(9):2142-2151. doi: 10.1111/dom.13796. Epub 2019 Jun 24.

PMID:
31144430
25.

GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men.

Skov-Jeppesen K, Svane MS, Martinussen C, Gabe MBN, Gasbjerg LS, Veedfald S, Bojsen-Møller KN, Madsbad S, Holst JJ, Rosenkilde MM, Hartmann B.

Bone. 2019 Aug;125:178-185. doi: 10.1016/j.bone.2019.05.014. Epub 2019 May 15.

PMID:
31100534
26.

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy.

Holst JJ.

Front Endocrinol (Lausanne). 2019 Apr 26;10:260. doi: 10.3389/fendo.2019.00260. eCollection 2019. Review.

27.

Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men.

Wewer Albrechtsen NJ, Mark PD, Terzic D, Hansen LH, Andersen UØ, Hartmann B, Carr RD, Gustafsson F, Deacon CF, Holst JJ, Goetze JP, Plomgaard P.

J Clin Endocrinol Metab. 2019 May 10. pii: jc.2019-00515. doi: 10.1210/jc.2019-00515. [Epub ahead of print]

PMID:
31074791
28.

Glucagon Receptor Signaling and Lipid Metabolism.

Galsgaard KD, Pedersen J, Knop FK, Holst JJ, Wewer Albrechtsen NJ.

Front Physiol. 2019 Apr 24;10:413. doi: 10.3389/fphys.2019.00413. eCollection 2019.

29.

GIP-induced vasodilation in human adipose tissue involves capillary recruitment.

Asmar M, Asmar A, Simonsen L, Dela F, Holst JJ, Bülow J.

Endocr Connect. 2019 May 1. pii: EC-19-0144.R1. doi: 10.1530/EC-19-0144. [Epub ahead of print]

30.

Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women.

Otten J, Ryberg M, Mellberg C, Andersson T, Chorell E, Lindahl B, Larsson C, Holst JJ, Olsson T.

Eur J Endocrinol. 2019 Jun 1;180(6):417-427. doi: 10.1530/EJE-19-0082.

31.

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes.

Hansen CS, Frandsen CS, Fleischer J, Vistisen D, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU, Dejgaard TF.

Front Endocrinol (Lausanne). 2019 Apr 12;10:242. doi: 10.3389/fendo.2019.00242. eCollection 2019.

32.

The incretin system in healthy humans: The role of GIP and GLP-1.

Holst JJ.

Metabolism. 2019 Jul;96:46-55. doi: 10.1016/j.metabol.2019.04.014. Epub 2019 Apr 25.

33.
34.

Long-acting glucagon-like peptide-1 receptor agonist-status December 2018.

Holst JJ.

Ann Transl Med. 2019 Mar;7(5):83. doi: 10.21037/atm.2019.01.09. No abstract available.

35.

Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.

Mulla CM, Goldfine AB, Dreyfuss JM, Houten S, Pan H, Pober DM, Wewer Albrechtsen NJ, Svane MS, Schmidt JB, Holst JJ, Craig CM, McLaughlin TL, Patti ME.

Obes Surg. 2019 Jul;29(7):2092-2099. doi: 10.1007/s11695-019-03845-0.

PMID:
30976983
36.

The Liver-α-Cell Axis and Type 2 Diabetes.

Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, Winther-Sørensen M, Suppli MP, Janah L, Gromada J, Vilstrup H, Knop FK, Holst JJ.

Endocr Rev. 2019 Oct 1;40(5):1353-1366. doi: 10.1210/er.2018-00251.

PMID:
30920583
37.

Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model.

Lin S, Stoll B, Robinson J, Pastor JJ, Marini JC, Ipharraguerre IR, Hartmann B, Holst JJ, Cruz S, Lau P, Olutoye O, Fang Z, Burrin DG.

Am J Physiol Gastrointest Liver Physiol. 2019 May 1;316(5):G641-G652. doi: 10.1152/ajpgi.00360.2018. Epub 2019 Mar 28.

PMID:
30920308
38.

No direct effect of SGLT2 activity on glucagon secretion.

Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, Chen L, Mandrup-Poulsen T, Ørskov C, Gribble FM, Reimann F, Wierup N, Tyrberg B, Holst JJ.

Diabetologia. 2019 Jun;62(6):1011-1023. doi: 10.1007/s00125-019-4849-6. Epub 2019 Mar 22.

PMID:
30903205
39.

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine.

Kuhre RE, Holst JJ.

J Vis Exp. 2019 Feb 26;(144). doi: 10.3791/58533.

PMID:
30882791
40.

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen J, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Holst JJ, Hartmann B, Hansen SH, Dragsted LO, Steensberg A, Mouritzen U, Hansen MB, Jeppesen PB.

Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. doi: 10.1016/S2468-1253(19)30077-9. Epub 2019 Mar 15.

PMID:
30880176
41.

Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.

Mezza T, Moffa S, Ferraro PM, Quero G, Capece U, Carfì A, Cefalo CMA, Cinti F, Sorice GP, Impronta F, Mari A, Pontecorvi A, Alfieri S, Holst JJ, Giaccari A.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2685-2694. doi: 10.1210/jc.2018-02804.

PMID:
30874733
42.

Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment.

Schiellerup SP, Skov-Jeppesen K, Windeløv JA, Svane MS, Holst JJ, Hartmann B, Rosenkilde MM.

Front Endocrinol (Lausanne). 2019 Feb 26;10:75. doi: 10.3389/fendo.2019.00075. eCollection 2019. Review.

43.

Bariatric surgery-which procedure is the optimal choice?

Madsbad S, Holst JJ.

Lancet. 2019 Mar 30;393(10178):1263-1264. doi: 10.1016/S0140-6736(19)30489-1. Epub 2019 Mar 6. No abstract available.

PMID:
30851878
44.

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.

Bergmann NC, Lund A, Gasbjerg LS, Jørgensen NR, Jessen L, Hartmann B, Holst JJ, Christensen MB, Vilsbøll T, Knop FK.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2953-2960. doi: 10.1210/jc.2019-00008.

PMID:
30848791
45.

Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion.

Martinussen C, Bojsen-Møller KN, Dirksen C, Svane MS, Kristiansen VB, Hartmann B, Holst JJ, Madsbad S.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3233-3244. doi: 10.1210/jc.2018-02661.

PMID:
30844053
46.

Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man.

Asmar A, Cramon PK, Simonsen L, Asmar M, Sorensen CM, Madsbad S, Moro C, Hartmann B, Jensen BL, Holst JJ, Bülow J.

J Clin Endocrinol Metab. 2019 Jul 1;104(7):2509-2519. doi: 10.1210/jc.2019-00004.

PMID:
30835273
47.

Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.

Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M.

Mol Syst Biol. 2019 Mar 1;15(3):e8793. doi: 10.15252/msb.20188793.

48.

Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling.

Galsgaard KD, Winther-Sørensen M, Pedersen J, Kjeldsen SAS, Rosenkilde MM, Wewer Albrechtsen NJ, Holst JJ.

Am J Physiol Endocrinol Metab. 2019 Apr 1;316(4):E660-E673. doi: 10.1152/ajpendo.00410.2018. Epub 2019 Feb 26.

PMID:
30807215
49.

Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.

Suhrs HE, Raft KF, Bové K, Madsbad S, Holst JJ, Zander M, Prescott E.

Int J Cardiol. 2019 May 15;283:28-34. doi: 10.1016/j.ijcard.2018.12.005. Epub 2019 Jan 2.

PMID:
30773266
50.

Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents.

Christiansen CB, Trammell SAJ, Wewer Albrechtsen NJ, Schoonjans K, Albrechtsen R, Gillum MP, Kuhre RE, Holst JJ.

Am J Physiol Gastrointest Liver Physiol. 2019 May 1;316(5):G574-G584. doi: 10.1152/ajpgi.00010.2019. Epub 2019 Feb 15.

PMID:
30767682

Supplemental Content

Loading ...
Support Center